NCM
NKTR icon

Nantahala Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Nantahala Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-112,946
Closed -$4.78M – 169
2025
Q4 		$4.78M Sell
112,946
-305,576
-73% -$17.1M 0.16% 102
2025
Q3 		$23.8M Sell
418,522
-291,239
-41% -$9.64M 0.83% 27
2025
Q2 		$18.3M Buy
709,761
+190,491
+37% +$2.14M 0.72% 30
2025
Q1 		$5.3M Sell
519,270
-1,397
-0.3% -$18.3K 0.21% 67
2024
Q4 		$7.26M Buy
520,667
+246,667
+90% +$4.35M 0.31% 59
2024
Q3 		$5.34M Hold
274,000
– – 0.27% 72
2024
Q2 		$5.1M Buy
274,000
+108,936
+66% +$2.3M 0.3% 60
2024
Q1 		$2.31M Buy
+165,064
New +$1.73M 0.13% 86

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Nantahala Capital Management's NKTR Position: Q1 2026 in Review

Nantahala Capital Management sold out of Nektar Therapeutics (NKTR) in Q1 2026, closing a stake of 112,946 shares — an estimated $4.78M sold.

Nantahala Capital Management first reported a position in NKTR in Q1 2024 and held it in 8 quarters. The position peaked at $23.8M in Q3 2025. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Nantahala Capital Management reported no remaining Nektar Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Nantahala Capital Management sold 112,946 Nektar Therapeutics shares in Q1 2026, an estimated $4.78M.
  • Nantahala Capital Management first reported a position in Nektar Therapeutics in Q1 2024 and held it in 8 quarters.
  • Nantahala Capital Management's Nektar Therapeutics position peaked at $23.8M in Q3 2025.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Nantahala Capital Management's 13F filing for Q1 2026, filed 15 May 2026.